• About us

    About us

    Futura Medical is a pharmaceutical company developing a portfolio of innovative products based on our proprietary, transdermal DermaSys® technology.

    Explore this section
    • Who we are
    • Our business model
    • Our strategy
    • Board of directors
  • What we do

    What we do

    Futura Medical is developing a portfolio of innovative products for two large markets, sexual health and pain.

    Explore this section
    • Our technology
    • Our product development pipeline
    • MED3000

      MED3000

      • MED3000 Overview
      • MED3000 CLINICAL PROGRAMME
      • MED3000 Commercial potential
    • Pain relief

      Pain relief

      • CBD100
      • TPR100 Clinical data
      • TPR100 Commercial potential
    • Products FAQs

      Products FAQs

      • MED3000 FAQs
      • FM71
  • Investor centre

    Investor centre

    Futura has a proven track record in delivery and completion of Research & Development projects up to value inflection points at which they are suitable for commercialisation partners.

    WEBCASTS

    Explore this section
    • Share price chart
    • Corporate documentation
    • Videos and webcasts

      Videos and webcasts

      • Videos
      • Webcasts
    • RNS
    • Alert service
    • Shareholder centre

      Shareholder centre

      • Investor contacts and advisors
      • Shareholder information
      • Financial calendar
      • Investor FAQs
      • Analyst Research
    • Corporate Governance
    • AIM rule 26
  • Media

    Media

    This section contains the latest RNS, news and videos.

    Explore this section
    • News
    • Event calendar
    • RNS
    • Videos
    • Alert service
  • Contact us
  • About us
    • Who we are
    • Our business model
    • Our strategy
    • Board of directors
  • What we do
    • Our technology
    • Our product development pipeline
    • MED3000
      • MED3000 Overview
      • MED3000 CLINICAL PROGRAMME
      • MED3000 Commercial potential
    • Pain relief
      • CBD100
      • TPR100 Clinical data
      • TPR100 Commercial potential
    • Products FAQs
      • MED3000 FAQs
        • What if Eroxon® is used in combination with PDE5is? Will post-approval studies be necessary?
      • FM71
  • Investor centre
    • Share price chart
    • Corporate documentation
    • Videos and webcasts
      • Videos
        • Futura Medical continues global expansion with Latin America announcement
        • Proactive Investor Video
        • Futura Medical PLC - Interim Results 2023
        • Fireside Chat with James Barder, CEO of Futura Medical
        • Futura Medical "absolutely delighted" with US commercialisation agreement
        • Futura Medical in discussions with US partners after gaining FDA approval
        • Futura Medical debuts Eroxon in UK and says "more launches coming"
        • Futura Medical expects FDA approval for topical ED treatment during Q2
        • Futura Medical "on track" for launch in H1 2023
        • Fireside chat - Dr Sidney Glina & Dr Wayne Hellstrom
        • Futura Medical cheers a "very productive six months, delivering on strategic objectives"
        • Futura Medical hails positive phase III results as it prepares for US FDA sign-off for ED gel
        • Futura Medical delighted with Cooper Health deal for MED3000
        • Futura Medical PLC "in a good place" as it moves towards launch of MED3000
        • Futura Medical signs South Korean licensing deal for erectile dysfunction gel MED3000
        • Futura Medical PLC reaches licensing deal for erectile dysfunction gel in Brazil and Mexico
        • Futura Medical’s CEO discusses £12m fundraising for MED3000
        • Futura Medical mark 'very busy year' with three landmark steps for erectile dysfunction gel MED3000
        • Futura Medical 'at final administrative stages of getting approval' for MED3000 in Europe
        • Futura Medical Announces Investment and Joint Collaboration to Commercialise MED3000 in China and South East Asia
        • Futura Medical announce regulatory and commercial progress on erectile disfunction gel
        • Futura Medical gets set to begin formal approval steps for erectile dysfunction drug
        • Futura Medical assessing commercialisation options for CBD100
        • Futura Medical's Ken James updates on EU and US regulatory progress for MED3000
        • Regulatory submissions for MED3000 remain on track
        • Full Year Results for the year ended 31 December 2019
        • Interview with Executive Director and Head of R&D - EU regulatory update and analysis of FM57
        • Interview with Executive Director and Head of R&D - Phase III Results
        • Fireside chat - Ken James & Dr Wayne Hellstrom
        • Interview of CEO – Interims
        • Introduction to Futura
        • Fireside Chat
        • Milestone for Futura Medical
        • On track with Phase 3 trial
        • New safety data on lead treatment
        • Futura Medical doses first patient in Phase 3 study
        • MED2005 treatment clinical trial set to begin
        • Phase 3 study kick off
        • MED2005 Clinical Programme Update
        • Preliminary results for the year ended 31 December 2017
        • MED2005 interview
        • MED2005 update
        • Positive market research data on MED2005
        • Interim results
        • Church and Dwight license termination
        • Critical step in the development of MED2005
        • Preliminary results
        • Significant interest for MED2005
        • UK licensing agreement
        • Futura Medical confirm US Food & Drug Administration agreement 'hot on heels' of EU regulatory steps
      • Webcasts
        • Interim Results 2023
        • Futura Medical Investor Seminar
        • Preliminary Results Webcast 2022
        • Futura Medical PLC - Interim Results
        • Highly positive FM71 Phase 3 Study Results with all primary and secondary endpoints achieved webcast
        • Preliminary Results Webcast 2021
        • Interim Results 2021
        • Preliminary Results Webcast 2020
        • Interim Results 2020
        • Full year results 2019
        • Preliminary Results Webcast
        • Research & Development seminar
        • Interim Results Webcast
        • FM57 Headline Results
    • RNS
    • Alert service
    • Shareholder centre
      • Investor contacts and advisors
      • Shareholder information
      • Financial calendar
        • Notice of Interim Results 2023
      • Investor FAQs
      • Analyst Research
    • Corporate Governance
    • AIM rule 26
  • Media
    • News
    • Event calendar
    • RNS
    • Videos
    • Alert service
  • Contact us
    Sitemap

    Sitemap

    • Home
    • Site essentials

    • Sitemap

    • About us
      • Who we are
      • Our business model
      • Our strategy
      • Board of directors
    • What we do
      • Our technology
      • Our product development pipeline
      • MED3000
        • MED3000 Overview
        • MED3000 CLINICAL PROGRAMME
        • MED3000 Commercial potential
      • Pain relief
        • CBD100
        • TPR100 Clinical data
        • TPR100 Commercial potential
      • Products FAQs
        • MED3000 FAQs
        • FM71
    • Investor centre
      • Share price chart
      • Corporate documentation
      • Videos and webcasts
        • Videos
        • Webcasts
      • RNS
      • Alert service
      • Shareholder centre
        • Investor contacts and advisors
        • Shareholder information
        • Financial calendar
        • Investor FAQs
        • Analyst Research
      • Corporate Governance
      • AIM rule 26
    • Media
      • News
      • Event calendar
      • RNS
      • Videos
      • Alert service
    • Contact us
    • Site Essentials
      • Accessibility
      • Terms of use
      • Privacy & cookies policies

    ©2023 Futura Medical

    • Sitemap
    • Contact us
    • Accessibility
    • Terms of use
    • Privacy & cookies policies

    ©2023 Futura Medical

    Designed and developed by
    jonesandpalmer.co.uk